HMGA1 Reprograms Somatic Cells into Pluripotent Stem Cells by Inducing Stem Cell Transcriptional Networks

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Shah, Sandeep N ^a   Kerr, Candace ^a   Cope, Leslie ^a   Zambidis, Elias ^a   Liu, Cyndi ^a   Hillion, Joelle ^a   Belton, Amy ^a   Huso, David L ^a   Resar, Linda M S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SOX2;

ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL SIZE; CMYC GENE; CONTROLLED STUDY; EMBRYO; EMBRYONIC STEM CELL; FIBROBLAST; GENE; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIN28 GENE; PLURIPOTENT STEM CELL; PROMOTER REGION; PROTEIN BINDING; SOMATIC CELL; SOX2 GENE; TERATOMA; TRANSCRIPTION REGULATION;

CELL DEDIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; EMBRYONIC STEM CELLS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HMGA1A PROTEIN; HUMANS; PLURIPOTENT STEM CELLS; PROMOTER REGIONS, GENETIC; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TETRAZOLIUM SALTS; THIAZOLES; TRANSCRIPTION FACTORS; TRANSDUCTION, GENETIC;

EID: 84869203467     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048533     Document Type: Article

References (69)

1. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
2. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. (2007) Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells. Science 318: 1917-1920.
3. Zhao R, Daley GQ, (2008) From fibroblasts to iPS cells: Induced pluripotency by defined factors. Journal of Cellular Biochemistry 105: 949-955.
4. Wang Y, Mah N, Prigione A, Wolfrum K, Andrade-Navarro M, et al. (2008) A Transcriptional Roadmap to the Induction of Pluripotency in Somatic Cells. Stem Cell Reviews and Reports 6: 282-296.
5. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, et al. (2008) Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 26: 101-106.
6. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, et al. (2008) Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451: 141-146.
7. Anokye-Danso F, Trivedi CM, Juhr D, Gupta M, Cui Z, et al. (2011) Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 8: 376-388.
8. Bock C, Kiskinis E, Verstappen G, Gu H, Boulting G, et al. (2011) Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 144: 439-452.
9. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507.
10. Mali P, Ye Z, Hommond HH, Yu X, Lin J, et al. (2008) Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. Stem Cells 26: 1998-2005.
11. Mali P, Chou BK, Yen J, Ye Z, Zou J, et al. (2010) Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells 28: 713-720.
12. Ohm JE, Mali P, Van Neste L, Berman DM, Liang L, et al. (2010) Cancer-Related Epigenome Changes Associated with Reprogramming to Induced Pluripotent Stem Cells. Cancer Research 70: 7662-7673.
13. Chou B-K, Mali P, Huang X, Ye Z, Dowey S, et al. (2011) Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res 21: 518-529.
14. Zhou G, Chen J, Lee S, Clark T, Rowley JD, et al. (2001) The pattern of gene expression in human CD34(+) stem/progenitor cells. Proc Natl Acad Sci U S A 98: 13966-13971.
15. Karp JE, Smith BD, Resar LS, Greer JM, Blackford A, et al. (2011) Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 117: 3302-3310.
16. Nelson DM, Joseph B, Hillion J, Segal J, Karp JE, et al. (2011) Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma 52: 1999-2006.
17. Dang CV, Resar LM, Emison E, Kim S, Li Q, et al. (1999) Function of the c-Myc oncogenic transcription factor. Exp Cell Res 253: 63-77.
18. Wood LJ, Maher JF, Bunton TE, Resar LM, (2000) The oncogenic properties of the HMG-I gene family. Cancer Res 60: 4256-4261.
19. Wood LJ, Mukherjee M, Dolde CE, Xu Y, Maher JF, et al. (2000) HMG-I/Y, a new c-Myc target gene and potential oncogene. Mol Cell Biol 20: 5490-5502.
20. Pedulla ML, Treff NR, Resar LM, Reeves R, (2001) Sequence and analysis of the murine Hmgiy (Hmga1) gene locus. Gene 271: 51-58.
21. Dolde CE, Mukherjee M, Cho C, Resar LMS, (2002) HMG-I/Y in human breast cancer cell lines. Breast Cancer Research and Treatment 71: 181-191.
22. Dhar A, Hu J, Reeves R, Resar LM, Colburn NH, (2004) Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. Oncogene 23: 4466-4476.
23. Takaha N, Resar LMS, Vindivich D, Coffey DS, (2004) High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. The Prostate 60: 160-167.
24. Hommura F, Katabami M, Leaner VD, Donninger H, Sumter TF, et al. (2004) HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells. Mol Cancer Res 2: 305-314.
25. Xu Y, Sumter TF, Bhattacharya R, Tesfaye A, Fuchs EJ, et al. (2004) The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res 64: 3371-3375.
26. Tesfaye A, Di Cello F, Hillion J, Ronnett BM, Elbahloul O, et al. (2007) The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res 67: 3998-4004.
27. Fusco A, Fedele M, (2007) Roles of HMGA proteins in cancer. Nat Rev Cancer 7: 899-910.
28. Di Cello F, Hillion J, Kowalski J, Ronnett BM, Aderinto A, et al. (2008) Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts. Molecular Cancer Therapeutics 7: 2090-2095.
29. Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, et al. (2008) The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res 68: 10121-10127.
30. Hillion J, Wood LJ, Mukherjee M, Bhattacharya R, Di Cello F, et al. (2009) Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res 7: 1803-1812.
31. Hristov AC, Cope L, Di Cello F, Reyes MD, Singh M, et al. (2010) HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod Pathol 23: 98-104.
32. Resar LMS, (2010) The High Mobility Group A1 Gene: Transforming Inflammatory Signals into Cancer? Cancer Research 70: 436-439.
33. Schuldenfrei A, Belton AK, Kowalski J, Talbot CC, Di Cello F, et al. (2011) HMGA1 Drives Stem Cell, Inflammatory Pathway, and Cell Cycle Progression Genes During Lymphoid Tumorigenesis. BMC Genomics 12: 549.
34. Belton A, Gabrovsky A, Iacobuzio-Donahue C, Huso DL, Resar LMS, (2012) HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One 7: e30034.
35. Shah SN, Resar LMS, (2012) High Mobility Group A1 and Cancer: Potential Biomarker and Therapeutic Target. Histol Histopathol 27: 567-579.
36. Hillion J, Smail S, Di Cello F, Belton A, Huso T, et al. (2012) The HMGA1a-COX-2 axis: A molecular pathway leading to tumor progression in human pancreatic adenocarcinoma Pancreatology. 12: 372-379.
37. Belton A, Paz-Priel I, Friedman AD, Huso D, Resar L (2012) The high mobility group A1 oncogene & NF-κB cooperate in malignant transformation. AACR 2012 [Abstract #3039].
38. Johnson KR, Cook SA, Davisson MT, (1992) Chromosomal localization of the murine gene and two related sequences encoding high-mobility-group I and Y proteins. Genomics 12: 503-509.
39. Johnson KR, Lehn DA, Elton TS, Barr PJ, Reeves R, (1988) Complete murine cDNA sequence, genomic structure, and tissue expression of the high mobility group protein HMG-I(Y). J Biol Chem 263: 18338-18342.
40. Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, et al. (2008) HMGA2 participates in transformation in human lung cancer. Mol Cancer Res 6: 743-750.
41. Hristov AC, Cope L, Reyes MD, Singh M, Iacobuzio-Donahue C, et al. (2009) HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol 22: 43-49.
42. Resar LM, Brodsky RA, (2011) "Let"-ing go with clonal expansion? Blood 117: 5788-5790.
43. Reeves R, Beckerbauer L, (2001) HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 1519: 13-29.
44. Moliterno A, Resar L (2011) AKNA: Another AT-hook transcription factor hooking up with inflammation? Cell Res 21L 1528-1530.
45. Reeves R, Edberg DD, Li Y, (2001) Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol 21: 575-594.
46. Fedele M, Pentimalli F, Baldassarre G, Battista S, Klein-Szanto AJ, et al. (2005) Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 24: 3427-3435.
47. Flohr AM, Rogalla P, Bonk U, Puettmann B, Buerger H, et al. (2003) High mobility group protein HMGA1 expression in breast cancer reveals a positive correlation with tumour grade. Histol Histopathol 18: 999-1004.
48. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, et al. (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436-442.
49. Sarhadi VK, Wikman H, Salmenkivi K, Kuosma E, Sioris T, et al. (2006) Increased expression of high mobility group A proteins in lung cancer. J Pathol 209: 206-212.
50. Zambidis ET, Park TS, Yu W, Tam A, Levine M, et al. (2008) Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood 112: 3601-3614.
51. Chaerkady C, Kerr CL, Marimuthu A, Kelkar DS, Kashyap MK, et al. (2009) Temporal analysis of neural differentiation using quantitative proteomics. J Proteome Res 8: 1315-1326.
52. Letzen BS, Liu C, Thakor NV, Gearhart JD, All AH, et al. (2010) MicroRNA expression profiling of oligodendrocyte differentiation from human embryonic stem cells. PLoS One 5: e10480.
53. Kitamura T, Koshino Y, Shibata F, Oki T, Nakajima H, et al. (2003) Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol 31: 1007-1014.
54. Mali P, Ye Z, Chou BK, Yen J, Cheng L, (2010) An improved method for generating and identifying human induced pluripotent stem cells. Methods Mol Biol 636: 191-205.
55. Chan EM, Ratanasirintrawoot S, Park IH, Manos PD, Loh YH, et al. (2009) Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotech 27: 1033-1037.
56. Liau SS, Jazag A, Whang EE, (2006) HMGA1 is a determinant of cellular invsiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res 66: 11613-11622.
57. Quandt K, Frech K, Karas H, Wingender E, Werner T, (1995) MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 23: 4878-4884.
58. Battista S, Pentimalli F, Baldassarre G, Fedele M, Fidanza V, et al. (2003) Loss of HMGA1 gene function affects embryonic stem cell lympho-hematopoietic differentiation. FASEB J 17: 1496-1498.
59. Zhou X, Benson KF, Ashar HR, Chada K, (1995) Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376: 771-774.
60. Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, (2010) Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A 107: 40-45.
61. Lin SL, Chang DC, Chang-Lin D, Lin CH, We DT, (2008) Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 14: 2115-2124.
62. Utikal J, Maherali N, Kulahert W, Hochedlinger K, (2009) Sox2 is dispensible for the reprogramming of melanocytes and melanoma cells into induce pluripotent stem cells. J Cell Sci 122: 3502-3510.
63. Nagai Ki, Ishii H, Miyoshi N, Hoshino H, Saito T, et al. (2011) Long-term culture following ES-like gene-induced reprogramming elicits an aggressive phenotype in mutated cholangiocellular carcinoma cells. Biochem Biophys Res Commun 395: 258-263.
64. Zhao T, Zhang ZN, Rong Z, Xu Y, (2011) Immunogenicity of induced pluripotent stem cells. Nature 474: 212-215.
65. Peng S, Chen LL, Lei XX, Yang L, Lin H, et al. (2011) Genome-wide studies reveal that Lin28 enhances the tanslation of genes important for growth and survival of human embryonic stem cells. Stem Cells 29: 496-504.
66. Andrews PW, Damjanov I, Simon D, Banting GS, Carlin C, et al. (1984) Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro. Lab Invest 50: 147-162.
67. Himes SR, Reeves R, Attema J, Nissen M, Li Y, et al. (2000) The role of high-mobility group I(Y) proteins in expression of IL-2 and T cell proliferation. J Immunol 164: 3157-3168.
68. Chaerkady R, Kerr CL, Kandasamy K, Marimuthu A, Gearhart JD, et al. (2010) Comparative proteomics of human embryonic stem cells and embryonal carcinoma cells. Proteomics 10: 1359-1373.
69. Zeller KI, Haggerty TJ, Barrett JF, Guo Q, Wonsey DR, et al. (2001) Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation. J Biol Chem 276: 48285-48291.